Connect with us

Hi, what are you looking for?

press release

Clinical study will evaluate psilocybin-assisted therapy for – Press Release

marlon lara nshbtdrhlnu unsplash

Consumer Health and Wellness Company Dear Pharma Co.s subsidiary MicroDoz Therapy Inc. is co-sponsoring a clinical study that is about to begin Psilocybin-assisted therapy in cannabis use disorderto be performed at the celebrated Johns Hopkins Center for Psychedelics and Consciousness Research.

LOVE is focused on commercializing innovative products that improve overall health and wellness improve quality of life through its exclusive production, sale and distribution licenses of patented therapeutic and pharmaceutical products throughout Europe, UK and North America.

“LOVE is actively working to identify and evaluate biotech and pharmaceutical solutions address addictionwith a view to expanding its pharmaceutical presence in the underserved addiction treatment market,” said SResident and CEO Zach Stadnyk.

That pilot study will be under the direction of dr. Albert Garcia Romeu and is intended to serve as the basis for large-scale research trials and the potential development and use of psilocybin products for addiction treatment, all of which would help build consumer confidence and drive future licensing and commercialization opportunities.

Details and proposed trial schedule: 12 cannabis use disorder patients will be enrolled between December and January to receive psilocybin-assisted therapy by sometime in Q1 2024 and follow-up is expected to be completed in Q2 and Q3 2024.

Photo of Marlon Lara on Unsplash

Source Story here

You May Also Like


State would join dozens of others in enacting legislation based on federal government’s landmark whistleblower statute, the False Claims Act

press release

With a deep understanding of the latest tech, Erbo helps businesses flourish in a digital world.

press release

#Automotive #Carbon #Canister #Market #Projected #Hit #USD New York, US, Oct. 24, 2022 (GLOBE NEWSWIRE) —  According to a comprehensive research report by Market...

press release

Barrington Research Analyst James C.Goss reiterated an Outperform rating on shares of IMAX Corp IMAX with a Price target of $20. As theaters...